Search

Displaying results 2801 - 2810 of 10000 in total
  1. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

  2. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Herborex Fort Lax Liq, Herbalax Forte No 70 Tab
  3. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  4. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  5. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407]. … In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background

    Synonyms: (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazoleCategories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  6. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters. … It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic acid as the most abundant species found in a proportion of 55% and 20% respectively.

  7. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]

    Categories: Hormonal Contraceptives for Systemic Use, Estrogens, Non-Steroidal
  8. Drug

    Norgestrel

    go.drugbank.com/drugs/DB09389
    Approved

    Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. … Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.

    Mixtures: Lo/Ovral, Lo-ovral-28Categories: Hormonal Contraceptives for Systemic Use
  9. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area. … The American Contact Dermatitis Society named Methylchloroisothiazolinone the Contact Allergen of the Year for 2013.

    Synonyms: 5-Chloro-N-methylisothiazolin-3-oneCategories: Compounds used in a research, industrial, or household setting
  10. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in

    Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-